Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Harmony Biosciences Holdings (HRMY) Shares Outstanding (Weighted Average) (2019 - 2025)

Harmony Biosciences Holdings' Shares Outstanding (Weighted Average) history spans 7 years, with the latest figure at $57.5 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 1.07% year-over-year to $57.5 million; the TTM value through Dec 2025 reached $57.5 million, up 1.07%, while the annual FY2025 figure was $57.5 million, 1.07% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $57.5 million at Harmony Biosciences Holdings, roughly flat from $57.6 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $59.9 million in Q3 2023 and bottomed at $56.8 million in Q1 2024.
  • The 5-year median for Shares Outstanding (Weighted Average) is $57.5 million (2021), against an average of $58.1 million.
  • The largest annual shift saw Shares Outstanding (Weighted Average) surged 630.25% in 2021 before it dropped 5.12% in 2024.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $57.5 million in 2021, then increased by 2.85% to $59.2 million in 2022, then grew by 0.5% to $59.5 million in 2023, then fell by 4.35% to $56.9 million in 2024, then increased by 1.07% to $57.5 million in 2025.
  • Per Business Quant, the three most recent readings for HRMY's Shares Outstanding (Weighted Average) are $57.5 million (Q4 2025), $57.6 million (Q3 2025), and $57.5 million (Q2 2025).